261 related articles for article (PubMed ID: 29521190)
1. BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series).
Frump A; Prewitt A; de Caestecker MP
Pulm Circ; 2018; 8(2):2045894018765840. PubMed ID: 29521190
[TBL] [Abstract][Full Text] [Related]
2. Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension.
Prewitt AR; Ghose S; Frump AL; Datta A; Austin ED; Kenworthy AK; de Caestecker MP
J Biol Chem; 2015 Jan; 290(2):960-71. PubMed ID: 25411245
[TBL] [Abstract][Full Text] [Related]
3. Genotype-phenotype effects of
Frump AL; Datta A; Ghose S; West J; de Caestecker MP
Pulm Circ; 2016 Dec; 6(4):597-607. PubMed ID: 28090303
[TBL] [Abstract][Full Text] [Related]
4. The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
Happé C; Kurakula K; Sun XQ; da Silva Goncalves Bos D; Rol N; Guignabert C; Tu L; Schalij I; Wiesmeijer KC; Tura-Ceide O; Vonk Noordegraaf A; de Man FS; Bogaard HJ; Goumans MJ
Cells; 2020 Jun; 9(6):. PubMed ID: 32521690
[No Abstract] [Full Text] [Related]
5. Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.
Ge X; Zhu T; Zhang X; Liu Y; Wang Y; Zhang W
Respir Res; 2020 Feb; 21(1):44. PubMed ID: 32028950
[TBL] [Abstract][Full Text] [Related]
6. Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension.
Frump AL; Lowery JW; Hamid R; Austin ED; de Caestecker M
PLoS One; 2013; 8(11):e80319. PubMed ID: 24224048
[TBL] [Abstract][Full Text] [Related]
7. Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism.
Chen X; Talati M; Fessel JP; Hemnes AR; Gladson S; French J; Shay S; Trammell A; Phillips JA; Hamid R; Cogan JD; Dawson EP; Womble KE; Hedges LK; Martinez EG; Wheeler LA; Loyd JE; Majka SJ; West J; Austin ED
Circulation; 2016 Jan; 133(1):82-97. PubMed ID: 26487756
[TBL] [Abstract][Full Text] [Related]
8. EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension.
Best DH; Sumner KL; Smith BP; Damjanovich-Colmenares K; Nakayama I; Brown LM; Ha Y; Paul E; Morris A; Jama MA; Dodson MW; Bayrak-Toydemir P; Elliott CG
Chest; 2017 Apr; 151(4):821-828. PubMed ID: 27884767
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and prognosis analysis of idiopathic and hereditary pulmonary hypertension patients with
Zhang X; Zhang C; Li Q; Piao C; Zhang H; Gu H
Pulm Circ; 2021; 11(4):20458940211044577. PubMed ID: 34966542
[TBL] [Abstract][Full Text] [Related]
10. BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension.
Talati M; West J; Blackwell TR; Loyd JE; Meyrick B
Am J Physiol Lung Cell Mol Physiol; 2010 Sep; 299(3):L363-73. PubMed ID: 20562228
[TBL] [Abstract][Full Text] [Related]
11. Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension.
Drake KM; Dunmore BJ; McNelly LN; Morrell NW; Aldred MA
Am J Respir Cell Mol Biol; 2013 Sep; 49(3):403-9. PubMed ID: 23590310
[TBL] [Abstract][Full Text] [Related]
12. EIF2AK4 mutation as "second hit" in hereditary pulmonary arterial hypertension.
Eichstaedt CA; Song J; Benjamin N; Harutyunova S; Fischer C; Grünig E; Hinderhofer K
Respir Res; 2016 Nov; 17(1):141. PubMed ID: 27809840
[TBL] [Abstract][Full Text] [Related]
13. BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.
Vengethasamy L; Hautefort A; Tielemans B; Belge C; Perros F; Verleden S; Fadel E; Van Raemdonck D; Delcroix M; Quarck R
Pflugers Arch; 2016 Nov; 468(11-12):1969-1983. PubMed ID: 27816994
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers.
Chida A; Shintani M; Yagi H; Fujiwara M; Kojima Y; Sato H; Imamura S; Yokozawa M; Onodera N; Horigome H; Kobayashi T; Hatai Y; Nakayama T; Fukushima H; Nishiyama M; Doi S; Ono Y; Yasukouchi S; Ichida F; Fujimoto K; Ohtsuki S; Teshima H; Kawano T; Nomura Y; Gu H; Ishiwata T; Furutani Y; Inai K; Saji T; Matsuoka R; Nonoyama S; Nakanishi T
Am J Cardiol; 2012 Aug; 110(4):586-93. PubMed ID: 22632830
[TBL] [Abstract][Full Text] [Related]
15. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension.
Hemnes AR; Brittain EL; Trammell AW; Fessel JP; Austin ED; Penner N; Maynard KB; Gleaves L; Talati M; Absi T; Disalvo T; West J
Am J Respir Crit Care Med; 2014 Feb; 189(3):325-34. PubMed ID: 24274756
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.
Pfarr N; Szamalek-Hoegel J; Fischer C; Hinderhofer K; Nagel C; Ehlken N; Tiede H; Olschewski H; Reichenberger F; Ghofrani AH; Seeger W; Grünig E
Respir Res; 2011 Jul; 12(1):99. PubMed ID: 21801371
[TBL] [Abstract][Full Text] [Related]
17. Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8.
Drake KM; Zygmunt D; Mavrakis L; Harbor P; Wang L; Comhair SA; Erzurum SC; Aldred MA
Am J Respir Crit Care Med; 2011 Dec; 184(12):1400-8. PubMed ID: 21920918
[TBL] [Abstract][Full Text] [Related]
18. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension.
Lavoie JR; Ormiston ML; Perez-Iratxeta C; Courtman DW; Jiang B; Ferrer E; Caruso P; Southwood M; Foster WS; Morrell NW; Stewart DJ
Circulation; 2014 May; 129(21):2125-35. PubMed ID: 24657995
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.
Hwangbo C; Lee HW; Kang H; Ju H; Wiley DS; Papangeli I; Han J; Kim JD; Dunworth WP; Hu X; Lee S; El-Hely O; Sofer A; Pak B; Peterson L; Comhair S; Hwang EM; Park JY; Thomas JL; Bautch VL; Erzurum SC; Chun HJ; Jin SW
Circulation; 2017 Jun; 135(23):2288-2298. PubMed ID: 28356442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
